Obermatt
See Similar Stocks →

Imprimis

NMQ:HROW · US4158581094
PharmaceuticalsMedium

360

22
EV / EBIT28
Price / Owner Earnings3
Owner Earnings Yield34
Dividend Yield1
Price/Sales67
EV / Gross Profit31
Price/Book5
Return on Capital49
Cash Return on Capital37
Return on Equity18
EBIT Margin30
Gross Profitability81
Accruals54
Owner Earnings Margin29
Sales growth70
Profit Growth78
Long-Term EPS Growth50
Owner Earnings Growth30
Reinvestment43
Price momentum45
Debt load7
Refinancing82
Debt Payback6
Liquidity54
Analyst ratings100
Opinion Changes50
Price Target Upside78
Market mood72
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Imprimis clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2006
Employees262
Websiteharrow.com
ISINUS4158581094
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OphthalmologyInflammationPain ManagementInfectious DiseasesBiotechnologyHealth CareMedical

Description

Harrow, Inc. (Harrow) is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the g…

Analysis

Hope premium

Harrow, Inc. carries what we call a hope premium: an average business trading at an ambitious price.

The price is expensive. You pay 420.6× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is solid and the balance sheet is fragile. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
35
2023202420252026

All-time high

35

Jun 2026

All-time low

4

Jan 2025

Average rank

22

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
30
46
48
Price/Earnings
16
17
1
38
Price/Book
5
5
16
8
Dividend Yield
1
1
1
1
Value (overall)
6
6
4
11

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Imprimis with its peers
Ocular Therapeutix
NMQ:OCUL
21
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ANI Pharma
NMQ:ANIP
98
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Scilex
NAQ:SCLX
6
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
CorMedix
NMQ:CRMD
95
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Alumis
NSQ:ALMS
22
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →